Combination treatment for advanced solid tumors using Trametinib, Everolimus, and Lenvatinib
Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial
This study is testing a new combination of three drugs to see if it can help people with advanced solid tumors, like liver cancer, feel better and improve their condition.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University Academic / other |
| Drugs / interventions | Trametinib, Lenvatinib |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04803318 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of a combination therapy using Trametinib, Everolimus, and Lenvatinib for patients with recurrent or refractory advanced solid tumors, including hepatocellular carcinoma. The study aims to measure tumor diameter and evaluate the efficacy of the treatment regimen after administration. Participants will be monitored for their response to the therapy, providing valuable data on its potential benefits and effectiveness.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 85 with recurrent or refractory advanced solid tumors and an expected life expectancy of more than three months.
Not a fit: Patients with benign tumors, a life expectancy of less than three months, or serious medical comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a new therapeutic option for patients with advanced solid tumors that have not responded to previous treatments.
How similar studies have performed: While this approach combines established therapies, the specific combination of Trametinib, Everolimus, and Lenvatinib for this indication is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recurrent/Refractory advanced solid tumors * Age between 18 and 85 years * Expected life expectancy is greater than three months Exclusion Criteria: * Benign tumor * Life expectancy is less than three months * Serious medical commodities * others
Where this trial is running
Guangzhou, Guangdong
- The Second Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Zhenfeng Zhang, MD, PhD — Second Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Zhenfeng Zhang, MD, PhD
- Email: zhangzhf@gzhmu.edu.cn
- Phone: +862039195966
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.